Ustekinumab
Treatment for Inflammatory Bowel Disease
Typical Dosage: IV induction followed by 90 mg SC every 8 weeks
Effectiveness
77%
Safety Score
60%
Clinical Trials
100
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
IV induction followed by 90 mg SC every 8 weeks
Time to Effect
6-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
60(Treat 60 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$3,000
Side Effect Mgmt:$1,000
Total Annual:$44,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$190,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$80,000
Cost per Remission
$146,667
Comparison vs Azathioprine
Cost Difference
+$42,500/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Ustekinumab Outcomes
for Inflammatory Bowel Disease
Efficacy Outcomes
Overall Effectiveness
+77%
Response Rate
+55%
Remission Rate
+30%
Common Side Effects
Nasopharyngitis
+11%
Headache
+10%
Injection site reactions
+5%
Infections
+22%
Serious infections
+1.5%
Sources:
Active Clinical Trials
9 active trials recruiting for Ustekinumab in Inflammatory Bowel Disease
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06453317RECRUITINGPHASE2
172 participants
INTERVENTIONAL
Lodz, Poland
Started: Feb 17, 2025
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
NCT06274554RECRUITINGPHASE3
120 participants
INTERVENTIONAL
New York, United States
Started: Oct 4, 2024
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT07444060RECRUITING
100 participants
OBSERVATIONAL
Hangzhou, China
Started: Mar 1, 2026
Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
NCT07529236RECRUITINGNA
40 participants
INTERVENTIONAL
Nice, France
Started: Apr 20, 2026
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031RECRUITING
239 participants
OBSERVATIONAL
Beijing, China +7 more
Started: Aug 1, 2024
Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
NCT05725876RECRUITINGPHASE1
56 participants
INTERVENTIONAL
Groningen, Netherlands
Started: Jan 6, 2025
Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods
NCT06849739NOT YET RECRUITING
60 participants
OBSERVATIONAL
Guangzhou, China
Started: Mar 2, 2025
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
NCT06520397RECRUITINGPHASE4
214 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 15, 2024
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Dothan, United States +47 more
Started: Apr 18, 2024
Completed Clinical Trials
9 completed trials for Ustekinumab in Inflammatory Bowel Disease
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03629379COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Leuven, Belgium
Started: Jan 22, 2019
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
NCT07697547COMPLETED
84 participants
OBSERVATIONAL
Shanghai, China
Started: Jul 1, 2023
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT02407236COMPLETEDPHASE3
961 participants
INTERVENTIONAL
Birmingham, United States +246 more
Started: Jul 10, 2015
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
NCT05029921COMPLETEDPHASE4
182 participants
INTERVENTIONAL
Beijing, China +28 more
Started: Dec 10, 2021
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
NCT03606499COMPLETED
111 participants
OBSERVATIONAL
Vandœuvre-lès-Nancy, France
Started: Sep 26, 2018
Ustekinumab Real World Evidence Study
NCT07748338COMPLETED
601 participants
OBSERVATIONAL
Bristol, United Kingdom +21 more
Started: Oct 30, 2019
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
NCT03942120COMPLETED
685 participants
OBSERVATIONAL
Busan, South Korea +42 more
Started: Apr 8, 2019
Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells
NCT03043677COMPLETED
45 participants
OBSERVATIONAL
Started: Apr 1, 2016
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
NCT01369355COMPLETEDPHASE3
1.28K participants
INTERVENTIONAL
Tucson, United States +219 more
Started: Sep 13, 2011
Showing 20 of 116 total trials